The UK and US have reached a major bilateral deal that will ensure zero import taxes on British medicine products being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has committed to boost spending on medicines through the NHS. This pledge ensures that duties on these key exports will remain at zero for a timeframe of the next three years.
This deal follows earlier statements to significantly raise tariffs on branded drug products, with figures mentioned up to double the cost.
"This arrangement with the United Kingdom bolsters the global environment for cutting-edge drugs and introduces much-needed balance to American-British medicine commerce," a statement declared.
Commercial Importance
Medicines represent one of the the United Kingdom's biggest exports to the US, which is clearly the primary market for leading British pharmaceutical firms.
Export figures indicate that in the one-year period leading up to September, the UK sold pharmaceutical products totaling billions to the US. This figure represented 17.4% of total UK exports in that timeframe.
"This agreement secures employment, increases investment and facilitates the UK to emerge as a international leader for medical research," a minister remarked.
Key NHS Changes
The deal entails several specific commitments from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it considers new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a aim to raise overall health service expenditure on medicines from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage manufacturers must pay back to the NHS to stay within budget will be limited at 15%. In the past, refunds topped twenty percent.
Recent Tensions
This agreement takes place against a long-running tension between the drug companies and the ministers over spending levels and NHS adoption.
The disagreement were heightened by assertions that US patients were paying significantly more for the equivalent treatments than consumers in the UK and Europe.
Recently, several large manufacturing plans in the UK have been paused or scrapped, while substantial investments have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS had to invest a greater share on drugs, noting that its spending on drugs had decreased as a share of its overall budget over the last ten years.
